Study reveals CAR T cells with different signaling types offer varying benefits in cancer treatment.

A recent study in Science Advances reveals how different types of CAR T cells, used in cancer immunotherapy, target and destroy cancer cells. Researchers found that CAR T cells with CD28.ζ signaling kill cancer cells quickly, while those with 4-1BB.ζ signaling maintain long-term cancer cell elimination. This discovery could help in developing CAR T therapies for a wider range of cancers, including challenging solid tumors.

2 months ago
5 Articles